{
    "paper_id": "PMC7188656",
    "metadata": {
        "title": "COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies",
        "authors": [
            {
                "first": "Bradley",
                "middle": [
                    "J."
                ],
                "last": "Monk",
                "suffix": "",
                "email": "Bradley.Monk@usoncology.com",
                "affiliation": {}
            },
            {
                "first": "Robert",
                "middle": [
                    "L."
                ],
                "last": "Coleman",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Kathleen",
                "middle": [
                    "N."
                ],
                "last": "Moore",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Thomas",
                "middle": [
                    "J."
                ],
                "last": "Herzog",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Angeles",
                "middle": [
                    "Alvarez"
                ],
                "last": "Secord",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Ursula",
                "middle": [
                    "A."
                ],
                "last": "Matulonis",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Brian",
                "middle": [
                    "M."
                ],
                "last": "Slomovitz",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Saketh",
                "middle": [
                    "R."
                ],
                "last": "Guntupalli",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "David",
                "middle": [
                    "M."
                ],
                "last": "O'Malley",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Dr. Bradley J. Monk wrote the first draft of this editorial and approved the final draft for submission. Dr. Monk's coauthors (Drs. Robert L. Coleman, Kathleen N. Moore, Thomas J. Herzog, Angeles Alvarez Secord, Ursula A. Matulonis, Brian M. Slomovitz, Saketh R. Guntupalli, and David M. O'Malley) contributed equally to this work and approved the final draft for submission.",
            "cite_spans": [],
            "section": "Author contributions",
            "ref_spans": []
        },
        {
            "text": "Dr. Bradley J. Monk reports personal fees from AbbVie, personal fees from Advaxis, personal fees from Agenus, personal fees from Amgen, personal fees from Aravive, personal fees from AstraZeneca, personal fees from Asymmetric Therapeutics, personal fees from Boston Biomedical, personal fees from ChemoCare, personal fees from ChemoID, personal fees from Clovis Oncology, personal fees from Easai, personal fees from Geistlich, personal fees from Genmab/Seattle Genetics, personal fees from GOG Foundation, personal fees from ImmunoGen, personal fees from Immunomedics, personal fees from Incyte, personal fees from Janssen/Johnson & Johnson, personal fees from Laekna Health Care, personal fees from Mateon (formally Oxigene), personal fees from Merck, personal fees from Mersana, personal fees from Myriad, personal fees from Nucana, personal fees from Oncomed, personal fees from Oncoquest, personal fees from Oncosec, personal fees from Perthera, personal fees from Pfizer, personal fees from Precision Oncology, personal fees from Puma, personal fees from Regeneron, personal fees from Roche/Genentech, personal fees from Samumed, personal fees from Takeda, personal fees from Tesaro/GSK, personal fees from VBL, personal fees from Vigeo, personal fees from Iovance, personal fees from Vavotar Life Science, personal fees from Senti Bio, personal fees from Akesio Bio, personal fees from Dicepheria, personal fees from Tarveda, outside the submitted work.",
            "cite_spans": [],
            "section": "Declaration of competing interest",
            "ref_spans": []
        },
        {
            "text": "Dr. Robert L. Coleman reports other from US Oncology Research, during the conduct of the study; grants and personal fees from AstraZeneca, grants from Merck, personal fees from Tesaro, personal fees from Medivation, grants and personal fees from Clovis Oncology, personal fees from Gamamab, grants and personal fees from Genmab, grants and personal fees from Roche/Genentech, grants and personal fees from Janssen, personal fees from Agenus, personal fees from Regeneron, personal fees from OncoQuest, outside the submitted work.",
            "cite_spans": [],
            "section": "Declaration of competing interest",
            "ref_spans": []
        },
        {
            "text": "Dr. Thomas J, Herzog reports personal fees from Johnson & Johnson, personal fees from AstraZeneca, Caris, Clovis Oncology, Roche, and Tesaro.",
            "cite_spans": [],
            "section": "Declaration of competing interest",
            "ref_spans": []
        },
        {
            "text": "Dr. Kathleen Moore reports personal fees and other from Astra Zeneca, grants, personal fees and other from Genentech/Roche, grants, personal fees and other from Immunogen, grants, personal fees and other from Clovis Oncology, grants, personal fees and other from Tesaro, personal fees and other from Pfizer, personal fees from Janssen, personal fees from Aravive, personal fees from VBL Therapeutics, personal fees and other from Onco Med, personal fees from Samumed, grants and other from Lilly, personal fees from Eisai, personal fees from Vavotar, personal fees from Abbvie, personal fees from Tarveda, outside the submitted work.",
            "cite_spans": [],
            "section": "Declaration of competing interest",
            "ref_spans": []
        },
        {
            "text": "Dr. Thomas Herzog reports personal fees from Johnson & Johnson, personal fees from Clovis Oncology, personal fees from AstraZeneca, personal fees from GSK/Tesaro, personal fees from Roche, personal fees from Caris, personal fees from Abbvie, outside the submitted work.",
            "cite_spans": [],
            "section": "Declaration of competing interest",
            "ref_spans": []
        },
        {
            "text": "Dr. Angeles Alvarez Secord reports grants from AbbVie, Amgen, AstraZeneca, Clovis Oncology, Astellas Pharma Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Endocyte, Exelixis, Incyte, Merck, PharmaMar, Immutep Ltd., Roche/Genentech, Seattle Genetics, Inc., Tesaro/GSK, VBL Therapeutics, National Cancer Trial Network; honoraria from Aravive, AstraZeneca, Clovis Oncology, Cordgenics, Eisai, Janssen/Johnson & Johnson, Merck, Mersana, OncoQuest, Roche/Genentech, Tesaro/GSK Advisory Boards; participation on Clinical Trial Steering Committees (uncompensated) for Roche/Genentech, and VBL Therapeutics; and member of GOG-Foundation Board of Directors, outside the submitted work.",
            "cite_spans": [],
            "section": "Declaration of competing interest",
            "ref_spans": []
        },
        {
            "text": "Dr. Ursula A. Matulonis reports personal fees from AstraZeneca, Myriad Genetics, Clovis Oncology, Merck, Eli Lilly, Mersana, Geneos, Fuji Film, Cerulean, Immunogen, and 2\u00d7 Oncology.",
            "cite_spans": [],
            "section": "Declaration of competing interest",
            "ref_spans": []
        },
        {
            "text": "Dr. Brian M. Slomovitz reports receiving consulting fees from AstraZeneca, Clovis Oncology, Incyte, Janssen, GSK/Tesaro, and Genentech/Roche.",
            "cite_spans": [],
            "section": "Declaration of competing interest",
            "ref_spans": []
        },
        {
            "text": "Dr. Saketh R. Guntupalli reports receiving consulting fees from AstraZeneca, Clovis Oncology, and Tesaro.",
            "cite_spans": [],
            "section": "Declaration of competing interest",
            "ref_spans": []
        },
        {
            "text": "Dr. David O'Malley reports personal fees and other from AstraZeneca, personal fees and other from Clovis Oncology, personal fees and other from Tesaro, personal fees and other from Immunogen, personal fees from Ambry, personal fees and other from Janssen/Johnson & Johnson, personal fees and other from Abbvie, personal fees and other from Regeneron, personal fees and other from Amgen, personal fees and other from Novocure, personal fees and other from Genentech/Roche, other from VentiRx, other from Array Biopharma, other from EMD Serono, other from Ergomed, other from Ajinomoto Inc., other from Ludwig Cancer Research, other from Stemcentrx, Inc., other from CERULEAN PHARMA, other from GOG Group, other from Bristol-Myers Squibb, other from Serono Inc., other from TRACON Pharmaceuticals, other from Yale University, other from New Mexico Cancer Care Alliance, other from INC Research, Inc., other from inVentiv Health Clinical, other from Iovance, other from PRA Intl, other from Agenus, outside the submitted work.",
            "cite_spans": [],
            "section": "Declaration of competing interest",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "World Health Organization",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "American Society for Clinical Oncology",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "World Health Organization",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "W.",
                    "middle": [],
                    "last": "Ouyang",
                    "suffix": ""
                },
                {
                    "first": "M.L.K.",
                    "middle": [],
                    "last": "Chua",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "JAMA Oncol.",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1001/jamaoncol.2020.0980"
                ]
            }
        },
        "BIBREF4": {
            "title": "Ovarian Cancer (Version 1.2020)",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "National Comprehensive Cancer Network",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Latest clinical evidence of maintenance therapy in ovarian cancer",
            "authors": [
                {
                    "first": "C.S.",
                    "middle": [],
                    "last": "Walsh",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Curr. Opin. Obstet. Gynecol.",
            "volume": "32",
            "issn": "",
            "pages": "15-21",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial",
            "authors": [
                {
                    "first": "R.T.",
                    "middle": [],
                    "last": "Penson",
                    "suffix": ""
                },
                {
                    "first": "R.V.",
                    "middle": [],
                    "last": "Valencia",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Cibula",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J. Clin. Oncol.",
            "volume": "38",
            "issn": "",
            "pages": "1164-1174",
            "other_ids": {
                "DOI": []
            }
        }
    }
}